Legend Biotech Corp (LEGN) - Total Assets
Based on the latest financial reports, Legend Biotech Corp (LEGN) holds total assets worth $1.71 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See LEGN total equity for net asset value and shareholders' equity analysis.
Legend Biotech Corp - Total Assets Trend (2017–2024)
This chart illustrates how Legend Biotech Corp's total assets have evolved over time, based on quarterly financial data.
Legend Biotech Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Legend Biotech Corp's total assets of $1.71 Billion consist of 76.9% current assets and 23.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.2% |
| Accounts Receivable | $124.89 Million | 7.5% |
| Inventory | $23.90 Million | 1.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $174.22 Million | 10.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Legend Biotech Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Legend Biotech Corp.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Legend Biotech Corp's current assets represent 76.9% of total assets in 2024, a decrease from 96.7% in 2017.
- Cash Position: Cash and equivalents constituted 17.2% of total assets in 2024, up from 0.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 10.4% of total assets.
Legend Biotech Corp Competitors by Total Assets
Key competitors of Legend Biotech Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Legend Biotech Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.86 | 4.98 | 5.14 |
| Quick Ratio | 2.80 | 4.90 | 5.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $808.43 Million | $1.08 Billion | $478.38 Million |
Legend Biotech Corp - Advanced Valuation Insights
This section examines the relationship between Legend Biotech Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.21 |
| Latest Market Cap to Assets Ratio | 1.94 |
| Asset Growth Rate (YoY) | -9.7% |
| Total Assets | $1.67 Billion |
| Market Capitalization | $3.25 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Legend Biotech Corp's assets above their book value (1.94x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Legend Biotech Corp's assets decreased by 9.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Legend Biotech Corp (2017–2024)
The table below shows the annual total assets of Legend Biotech Corp from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.67 Billion | -9.65% |
| 2023-12-31 | $1.85 Billion | +38.89% |
| 2022-12-31 | $1.33 Billion | +18.89% |
| 2021-12-31 | $1.12 Billion | +55.03% |
| 2020-12-31 | $722.09 Million | +150.98% |
| 2019-12-31 | $287.71 Million | -32.94% |
| 2018-12-31 | $429.05 Million | +79.75% |
| 2017-12-31 | $238.69 Million | -- |
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more